COVID-19 Vaccines
Conditions
Keywords
MVA-SARS-COV-2, MVA-SARS-2-ST
Brief summary
This will be a phase I, single-center trial, including a total of 30 participants in two cohorts. Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen. Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST
Interventions
BIOLOGICALMVA-SARS-2-ST
In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
Sponsors
Hannover Medical School
German Center for Infection Research
IDT Biologika
Universitätsklinikum Hamburg-Eppendorf
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
The subject must not be enrolled before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria listed below will be included in the study. 1. Signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures 2. Healthy men or women, aged ≥ 18 ≤ 60 at day of inclusion having received either 1. primary immunization (cohort 1) with any regimen using any EU marketed SARS- CoV-2 vaccine or 2. subsequently booster immunization (cohort 2) with any EU marketed mRNA vaccine at least 3 months prior to enrollment 3. Adults with SARS-CoV-2 specific IgG concentration between 10 RU/ml and 1200 RU/ml determined by Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) 4. Males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (Section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study. or Females without child-bearing potential defined as follows: * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or * hysterectomy or uterine agenesis or * ≥ 50 years and in postmenopausal state \> 1 year or * \< 50 years and in postmenopausal state \> 1 year with serum FSH \> 40 IU/l and serum estrogen \< 30 ng/l or a negative estrogen test, both at screening 5. Normal pulmonary function: FEV1 predicted ≥ 80% and FEV1/FVC \> 70% 6. Body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening 7. Subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial
Exclusion criteria
Subjects are excluded from the study if any of the following criteria are met at screening or on dosing day. 1. Previous MVA or rMVA vaccination 2. Known allergy to the components of the SARS-CoV-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances 3. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine 4. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times 5. Any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator 6. Evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product 7. Current smoking/ vaping or smoking /vaping in the previous year. 8. Clinically relevant findings in ECG 9. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes 10. Asthma, chronic obstructive pulmonary disease or other lung disease 11. Respiratory tract infection in the 4 weeks prior to study treatment 12. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child 13. Known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine. 14. Treatment with ß-adrenoceptor antagonists 15. Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males) 16. Drug abuse or positive drug screening 17. Any positive result for HIV1/2, HCV antibody or HBs antigen testing 18. Moderate or severe illness and/or fever \>38 °C within 1 week prior to vaccination 19. History of blood donation within 60 days of enrollment or plans to donate within the treatment phase 20. Participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study 21. Investigator or employee of the study site or Sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST | day 0 | Occurrence of solicited local reactogenicity signs and symptoms |
| Change from baseline of pulmonary function associated with MVA-SARS-2-ST | day 0 (2h), day 1, 3, 7, 14, 28, 56, 140 | Change from baseline of pulmonary function measured by spirometry as forced vital capacity (FVC) (%) |
| Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST | day 0 | Occurrence of solicited systemic reactogenicity signs and symptoms vaccination |
| Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST | from day 0 to day 28 after vaccination | Occurrence of unsolicited adverse events (AE) |
| Change of safety laboratory measures associated with MVA-SARS-2-S | day 1, 3, 7, 14, 28, 56, 140 | Change from baseline of safety laboratory measures |
| Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST | through study completion, an average of 5 month | Occurrence of serious adverse events (SAE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate immunogenicity of the candidate MVA-SARS-2-ST | day 7, 14, 28, 56 and 140 | Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in blood |
Countries
Germany
Contacts
PRINCIPAL_INVESTIGATORJens Hohlfeld, Prof.
Hannover Medical School, Department of Respiratory Medicine and Fraunhofer ITEM, Division of Clinical Airway Research
STUDY_CHAIRReinhold Förster, Prof.
Hannover Medical School Institute of Immunology
Outcome results
None listed